Publication of List of Manufacturers Suspended from Licensing for the Manufacture of Therapeutic Goods – 30 November 2023

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth Parliament, addresses the regulation of therapeutic goods in Australia, including medicines, medical devices, and blood and tissues. This legislation aims to protect public health by ensuring that therapeutic goods available in Australia are of acceptable quality, safety, and efficacy. The Act provides a legal framework for the control of therapeutic goods through the Therapeutic Goods Administration (TGA), which operates under the Department of Health and Aged Care. The policy objective of the Act is to safeguard the health and safety of Australians by effectively regulating the importation, manufacture, and distribution of therapeutic goods. On 30 November 2023, Katherine Clark, a Delegate of the Secretary of the Department of Health and Aged Care, published details regarding the suspension of a Licence to Manufacture Therapeutic Goods held by AEGROS LIMITED, effective from 23 September 2023 to 25 March 2024. This action was taken under Section 41(1)(d) of the Therapeutic Goods Act 1989, at the request of the manufacturer, to address potential quality or safety issues with the therapeutic goods produced. This suspension is a demonstration of the TGA's commitment to maintaining high standards in the manufacture of therapeutic goods in Australia.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities and persons involved in the manufacture, supply, and advertising of therapeutic goods in Australia, which includes medicines, medical devices, blood, and tissues. The act ensures that these goods meet safety, quality, and efficacy standards and is administered by the Therapeutic Goods Administration (TGA), an agency of the Commonwealth of Australia. This act applies nationally across all states and territories, governing entities such as pharmaceutical companies, medical device manufacturers, and individuals who produce or supply therapeutic goods for commercial purposes. The scope of the act is broad, covering a wide range of therapeutic goods and the activities related to their production and distribution. While the act generally applies to all entities and individuals within the Australian jurisdiction, there are specific exclusions and exemptions outlined in the legislation, such as goods used for personal use, those intended for export only, and certain types of blood and tissues. The application of the Therapeutic Goods Act 1989 is further extended and detailed through subordinate instruments, such as regulations and guidelines, which provide additional specifications and enforcement mechanisms. These subordinate instruments help in the practical application of the act by clarifying certain provisions and providing detailed procedures for compliance and enforcement.

Key Provisions

The Therapeutic Goods Act 1989, through Section 41(1)(d), empowers the Secretary of the Department of Health and Aged Care, Therapeutic Goods Administration, to suspend a licence to manufacture therapeutic goods. In this specific case, the Secretary has exercised this power to suspend the licence held by AEGROS LIMITED, Licence No. MI-19042005-LI-000513-1, located at 5 Eden Park Drive, North Ryde, NSW, 2113, at the manufacturer's request. The suspension is effective from 23 September 2023 until 25 March 2024. This suspension is intended to ensure that the therapeutic goods produced by the manufacturer meet the required standards of safety, quality, and efficacy, as stipulated by the Act. The Therapeutic Goods Act 1989 imposes several obligations on manufacturers of therapeutic goods, including maintaining high standards of quality, safety, and efficacy. A manufacturer holding a licence must comply with the requirements outlined in the Act and any associated regulations. This includes ensuring that their manufacturing processes and facilities adhere to Good Manufacturing Practice (GMP) standards, which are designed to prevent contamination and ensure the integrity of the therapeutic goods produced. Additionally, manufacturers must submit regular reports to the Therapeutic Goods Administration, detailing their compliance with the Act and any incidents or issues that may impact the quality or safety of their products. Failure to comply with the provisions of the Therapeutic Goods Act 1989 can result in serious consequences for the manufacturer. Offences under the Act can lead to criminal charges, with penalties including fines of up to $1,260,000 for a corporation and imprisonment for up to 10 years for an individual, as stipulated in Section 18(2) of the Act. Furthermore, civil penalties may also apply, with fines up to $1.1 million for corporations and $210,000 for individuals, as outlined in Section 41HA. In addition to financial penalties, the suspension of a manufacturer’s licence, as seen in this case with AEGROS LIMITED, serves as a significant regulatory action that can severely impact the manufacturer's ability to operate within the Australian market. In summary, the Therapeutic Goods Act 1989 provides a framework for the regulation of therapeutic goods in Australia, ensuring that manufacturers adhere to stringent quality, safety, and efficacy standards. The suspension of AEGROS LIMITED’s licence is a clear demonstration of the regulatory oversight exercised by the Therapeutic Goods Administration. This action not only highlights the importance of compliance with the Act but also underscores the potential consequences for manufacturers who fail to meet these critical standards. The Act thus plays a vital role in protecting public health by ensuring that only safe and effective therapeutic goods are available in the Australian market.